| Application | Recommended Dilution |
|---|---|
| WB | 1:500-1:5000 |
| IHC | 1:50-1:200 |
Epidermal growth factor receptor (EGFR) stands as one of the most extensively studied receptor tyrosine kinases in cancer biology, serving as a critical regulator of cell proliferation, survival, and differentiation. As a proto-oncogene frequently dysregulated in epithelial malignancies, EGFR remains a central focus for researchers investigating oncogenic signaling pathways and therapeutic resistance mechanisms.
This recombinant monoclonal antibody, clone 5D4, offers the consistency and reliability that demanding research applications require. Produced using recombinant technology with a defined sequence, this rabbit IgG eliminates the lot-to-lot variability that can compromise longitudinal studies and reproducibility across experiments. The sequence-defined nature of recombinant antibodies ensures that your results today will be comparable to those generated months or years from now.
Validation studies demonstrate robust performance across multiple experimental platforms. In western blot applications, this antibody successfully detects EGFR in HeLa, L02, and HepG2 whole cell lysates at dilutions ranging from 1:500 to 1:5000. The observed band at approximately 150 kDa, slightly higher than the predicted molecular weight, reflects the extensive glycosylation characteristic of this membrane receptor in its mature, fully processed form. For immunohistochemistry, validated staining in paraffin-embedded human glioma and cervical cancer tissues at 1:50 to 1:200 dilutions confirms utility for tissue-based investigations of EGFR expression patterns.
Whether you are characterizing EGFR expression in cancer cell models, investigating signal transduction cascades, or examining receptor localization in tumor specimens, this antibody provides a dependable tool for advancing your understanding of EGFR biology in human samples.
Email: support@cusabio.com
Distributors Worldwide